Metabolism of NNK in Japanese Americans

Description

The risk of lung cancer varies by individual and by ethnic/racial group. In this study the investigators will explore how individual differences in the metabolism of a tobacco-specific lung carcinogen may contribute to the variable risk of lung cancer between ethnic/racial groups. In this 10 day clinical trial, Japanese Americans will smoke a cigarette containing deuterium-labeled 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. The study cigarette will be smoked for 7 days. This will allow for NNK metabolic profiling and determining the effect of CYP2A6 genotype on the level of NNK α-hydroxylation in Japanese Americans smokers using \[pyridine- D4\]-NNK containing cigarettes.

Conditions

Smoking

Talk to us

Study Overview

On this page

Study Details

Study overview

The risk of lung cancer varies by individual and by ethnic/racial group. In this study the investigators will explore how individual differences in the metabolism of a tobacco-specific lung carcinogen may contribute to the variable risk of lung cancer between ethnic/racial groups. In this 10 day clinical trial, Japanese Americans will smoke a cigarette containing deuterium-labeled 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific lung carcinogen. The study cigarette will be smoked for 7 days. This will allow for NNK metabolic profiling and determining the effect of CYP2A6 genotype on the level of NNK α-hydroxylation in Japanese Americans smokers using \[pyridine- D4\]-NNK containing cigarettes.

STUDY 2: CLINICAL PROTOCOL Metabolism of NNK Among Japanese Americans

Metabolism of NNK in Japanese Americans

Condition
Smoking
Intervention / Treatment

-

Contacts and Locations

Honolulu

University of Hawaii Cancer Center, Honolulu, Hawaii, United States, 96813

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Japanese American - one, but preferably 2 biological parents of Japanese descent
  • 2. 21 years or older
  • 3. Daily smoker
  • 4. Eligible urinary ratios of total 3-hydroxycotinine to cotinine (3HC/COT):
  • * "Little or no-CYP2A6 activity" defined as a 3-hydroxycotinine:cotinine ratio of \<0.6 or
  • * "Relatively high" CYP2A6 activity defined as a 3-hydroxycotinine:cotinine ratio of \>3.0.
  • 5. Stable and good physical and mental health
  • 6. Provided written informed consent to participate in the study
  • 1. Unwilling to avoid other nicotine containing products during the study and no use of any nicotine-containing products except cigarettes for 1 week prior to their study visits
  • 2. Currently taking any medications that affect relevant metabolic enzymes
  • 3. Experiencing medical conditions that might affect biomarkers of exposure and effect
  • 4. Pregnant or nursing or planning on becoming pregnant during the study
  • 5. Unable to read and understand English

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Masonic Cancer Center, University of Minnesota,

Dorothy K Hatsukami, Ph.D, PRINCIPAL_INVESTIGATOR, Masonic Cancer Center, University of Minnesota

Study Record Dates

2024-12-31